Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 12Carcinoma, Hepatocellular 11Nasopharyngeal Carcinoma 8Esophageal Squamous Cell Carcinoma 8Carcinoma, Non-Small-Cell Lung 8Stomach Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Colorectal Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4Liver Neoplasms 4Carcinoma, Transitional Cell 4Sarcoma 3Neoplasm Metastasis 3Lung Neoplasms 3Hypopharyngeal Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumor 2Recurrence 2Lymphoma 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Upper Tract Urinary Carcinoma 1Thyroid Neoplasms 1Thymic epithelial tumor 1Thoracic Neoplasms 1

Interventions

toripalimab 1tislelizumab 1liposomal doxorubicin 1disitamab vedotin 1RC48 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Muscle Invasive Bladder Cancer × toripalimab × Clear all
NCT05979740 2023-08-31

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

RenJi Hospital

Phase 2 Unknown
6 enrolled
Genitourinary

Muscle Invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡